Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
Status unconfirmed · Phase 2
Conditions studied: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Uterine Cancer, Mesotheliomas, Gastrointestinal Cancers, Cervical Cancer
In brief
To determine treatment response to surgical debulking and intra-operative Intraperitoneal Hyperthermic Chemotherapy (IPHC) in patients with the following malignancies: Gynecologic cancers (ovarian, primary peritoneal or fallopian tube, and uterine/cervical cancers). Mesotheliomas. GI cancers (Gallbladder, liver, small intestine, pancreas, stomach, colon, appendix). To monitor the toxicities and complications of this treatment regimen. To measure treatment related QOL changes after IPHC.
Key facts
- Study ID
- NCT02349958
- Run by
- Bay Area Gynecology Oncology
- People needed
- 200
- Starts
- 2006-09-01
- Expected to finish
- 2022-01-01
- Last updated by the study team
- 2019-04-16
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- James Lilja — Los Gatos, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.